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The situation regarding public health responses to the COVID-19 pandemic is rapidly evolving. Up-to-
date information can be found in the guidelines prepared by national public health sources and the 
regular updates from the European Centre for Disease Prevention and Control and the World Health 
Organization. The EMCDDA has created a COVID-19 resource hub for people who use drugs and drug 
service providers.  
 
 
Summary 
Since the start of 2020, European countries have been experiencing an unprecedented public health 
threat with the emergence of the coronavirus disease (COVID-19). In order to investigate the effects 
and implications of this pandemic for drug services in Europe, the European Monitoring Centre for 
Drugs and Drug Addiction instigated a mixed-method trendspotter study to provide a snapshot of the 
current situation. This exercise provides a rapid assessment of the state of play in respect to the 
impact of COVID-19 on service provision and help-seeking behaviour among people who use drugs.  
Preliminary findings suggest there has been a decline in the availability of European drug services 
during the first two months of the pandemic, both those providing treatment and those providing harm 
reduction interventions. Drug services have largely been affected in similar ways to other frontline 
health services, with some providers forced to close down or restrict access. Services still working 
directly with clients need to implement new hygiene and social distancing measures which can be 
especially challenging in some of the settings in which drug services operate. It is also reported that 
services are increasingly using mobile or online platforms to mitigate for the current difficulties in 
providing face-to-face care. 
While they are trying to keep operations running efficiently, service providers have identified a number 
of specific new COVID-19-related challenges. These include: accessing sufficient personal protective 
equipment for staff; informing and educating clients about COVID-19 risks; managing infected clients 
and concerns about staff vulnerability to infection; helping more marginalised clients to access 
essential hygiene-related services; challenges linked to the use of remote technology (phone and 
video); staffing shortages; problems enrolling new clients and managing the demand for substitution 
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treatment; and the need to mitigate potential risks of unintended consequences associated with 
rapidly implemented adaptations to normal working practices. 
In respect to implications for help-seeking behaviour, an analysis of data from four countries with 
information available on treatment demand between January and March 2020 shows a steady decline 
in both new and all treatment entrants. This includes a marked overall drop of more than 50 % in 
opioid-using entrants over this period. While not necessarily generalisable to other countries, this 
suggests that a combination of public health confinement measures in combination with service 
closures and/or reduction in service availability may be taking a toll. 
The study also provides some insight into the innovations adopted by drug services across Europe in 
response to the COVID-19-related challenges. When asked their opinions on what the post-COVID-
19 ‘new normal’ might look like for drug services in Europe, experts highlighted a number of changes 
that they considered would be advantageous to maintain after the first wave of the crisis has passed. 
The most commonly cited examples included the new flexibility associated with opioid substitution 
treatment service models and the potential future use of telemedicine approaches. 
Introduction 
In response to the COVID-19 pandemic in February 2020, European countries have implemented a 
range of containment and mitigation measures to reduce the spread of the virus among their general 
populations. While people who use drugs run the same risk of infection with COVID-19 as the general 
population, they also face additional risks and vulnerabilities that need both consideration and 
mitigation (EMCDDA, 2020). The emerging evidence suggests that European drug services, like other 
healthcare providers, face a range of challenges in maintaining adequate provision for their clients. In 
many instances, services have had to be innovative and adapt very rapidly in response to the new 
and fast-changing landscape in the wake of the pandemic and associated national control measures. 
Very limited information is available at European level on the challenges faced and the adaptations 
made by drug treatment and harm reduction services following the emergence of COVID-19 in the 
Member States. In order to gain an insight into the impact on drug services and the adaptations being 
made since the beginning of the pandemic in Europe, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) initiated an investigative rapid assessment using the agency’s trendspotter 
methodology. This study was conducted in April 2020. The primary aim of the study was to provide a 
rapid snapshot that would increase our understanding on the impact of COVID-19 on the demand for 
and provision of drug services across Europe. 
Recognising the potentially harmful consequences of COVID-19 and related restrictions on drug 
services for people with more severe drug problems, including opioid users and people who inject 
drugs, this first EMCDDA briefing concentrates on the implications for drug treatment and harm 
reduction services for these client groups. Future investigative rounds will explore the impact on 
service provision for stimulant and cannabis users as well as focusing in more detail on interventions 
delivered in prisons, interventions in recreational settings and online interventions. 
The trendspotter methodology 
The trendspotter methodology is based on the triangulation of a range of investigative approaches 
and data collection from multiple qualitative and quantitative sources with a systematic analysis 
incorporating the use of expert opinion (EMCDDA, 2018). Specifically, for this COVID-19 impact 
study, the methodology was adapted to suit online investigation, taking into account the national 
emergency restrictions on both the EMCDDA team and the study participants (Figure 1). The study 
has been divided into a number of investigative and reporting waves, with the first wave focusing on 
the impact of COVID-19 on drug service provision and help-seeking.  
EMCDDA Trendspotter briefing I Impact of COVID-19 on drug services and help-seeking in Europe 
 
 
3 
 
For this current online briefing, the results of the following data collection exercises have been 
brought together in the analysis: 
■ review of the international literature and available epidemiological data; 
■ three online expert surveys, sent to the Reitox network of national focal points, an existing 
EMCDDA network of trendspotters, and a sample of European professionals in the treatment 
and harm reduction field; 
■ a mini-survey, the European Web Survey on Drugs: COVID-19, in 21 languages, targeting 
adults aged 18 years or over with experience of illicit drug use, aimed at gathering information 
on changes in drug consumption behaviours in Europe due to COVID-19, and also including 
questions on help-seeking and perceptions of service availability; 
■ four virtual facilitated groups made up of 34 European drug professionals, researchers and 
representatives of advocacy groups, and one virtual facilitated group of 10 Italian drug 
professionals. 
 
Where results are literature-based, references are cited; otherwise, findings are based on EMCDDA 
monitoring and the qualitative sources described above.  
This briefing summarises the study findings of the first wave of the study focusing on drug services. 
This will be followed shortly by a second online briefing reporting on a second wave focusing on the 
findings on the impact of COVID-19 on patterns of use and harms in Europe.  
 
FIGURE 1 
Adapted trendspotter methodology, April 2020 
 
What have been the main changes and challenges for European drug services 
since the emergence of COVID-19? 
A survey of national focal points carried out during April 2020 suggests that the impact of COVID-19 
and related national containment measures appears to have resulted in reduction in the availability 
and provision of treatment and harm reduction services in most European countries (Figures 2 and 3).  
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FIGURE 2  
Changes in the availability and provision of drug treatment services in the EU and Norway 
since COVID-19 containment measures have been implemented, based on reporting from 
Reitox national focal points 
 
FIGURE 3  
Changes in the availability and provision of harm reduction services in the EU and Norway 
since COVID-19 containment measures have been implemented, based on reporting from 
Reitox national focal points 
 
As is the case for many general healthcare providers during this public health crisis, drug services 
have needed to remain operational under restricted conditions. This has often required significant 
adaptations to established service delivery models. In some countries or regions, drug services are 
reported to have been discontinued or closed down. In particular, specialised outpatient facilities that 
have not been able to implement the required national protection measures have been closed in a 
number of countries. Specific examples of services that have suspended provision include drop-in 
centres and low-threshold agencies in some regions of France and Italy, and drug consumption 
rooms in Norway and in some German cities (Figures 4 and 5). 
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FIGURE 4  
Closure or significant reduction of drug treatment services since COVID-19 measures were 
implemented in the EU countries and Norway, based on reporting from Reitox national focal 
points 
 
 
 
FIGURE 5 
Closure or significant reduction of harm reduction services since COVID-19 measures were 
implemented in the EU countries and Norway, based on reporting from Reitox national focal 
points  
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As is the case for most public and specialist health services, the operational models for drug services 
often require face-to-face contact with individuals or groups. This means that services have needed to 
implement fundamental operational changes. Adaptations reported have included the provision of 
protective equipment for staff, the introduction of protocols for reducing the risk of transmission to 
both staff and clients, the implementation of strict social distancing rules and the use of physical 
barriers to protect staff who interact with clients. Where this is feasible, services have largely replaced 
face-to-face contacts with telemedicine (by phone or video). Service providers also noted there was a 
need to increase the capacity of their outreach programmes to cater for the needs of more socially 
excluded and marginalised groups. 
Preliminary findings from this study highlight a number of significant challenges faced by both drug 
services and their clients: 
■ Access to personal protective equipment (PPE) for staff. Reports highlight the serious 
difficulties faced by drug services in accessing PPE at the beginning of the pandemic in many 
countries. For example, Italian drug treatment professionals reported major shortages of PPE 
during the first three weeks of the crisis. This undoubtedly reflects the overall shortage of 
such equipment for healthcare professionals in most EU countries during the early stages of 
the pandemic. By mid-April, drug professionals surveyed in this study reported that access to 
PPE for drug service staff had greatly improved. 
■ Informing and educating clients about COVID-19. Challenges reported here included 
persuading clients of the importance of essential prevention measures to protect both 
themselves and the staff. Respecting social distancing measures appeared to be particularly 
challenging for certain client groups. In addition, some marginalised groups were reported to 
be ‘out of the loop’ in terms of being updated on national public health guidance during this 
fast-evolving crisis. This was particularly evident when containment measures and stay-at-
home orders were introduced, often clashing with the street-based lifestyle of some 
populations, including homeless people and undocumented migrants. In many instances, 
however, professionals in our study were positive about the collaboration between clients and 
staff on respecting rules and keeping preventive measures in place. 
■ Management of clients infected with COVID-19. Most health professionals surveyed did 
not report identified cases of infected clients. However, seven experts reported five or fewer 
COVID-19 cases among their clients, two reported more than 10 cases and one Belgian 
doctor involved in opioid substitution treatment (OST) provision reported that two of his clients 
had died from COVID-19. These experts reported some difficulties with management of 
clients with COVID-19, in terms of both maintaining quarantine measures and dealing with 
client anxiety about the situation, especially among more marginalised users. 
■ Concern about staff vulnerability to infection. Many workers in drug services are exposed 
to a similar risk of infection to other frontline healthcare professionals during this pandemic. 
And closure of some drug services has resulted in additional pressure on those staff who 
remain working in operational services. Reports highlight particular challenges for frontline 
services that were obliged to take on increased responsibilities while at the same time having 
to implement new service models in response to COVID-19 prevention measures. 
■ Staff shortages. These were commonly reported as a result of a number of factors, including 
staff being unable to work because of family responsibilities (e.g. childcare), staff being 
quarantined, and alternating shifts to reduce infection risks to the whole staff resulting in fewer 
staff available at any given time. Alternating shifts was a common feature of the adapted work 
schedule in a number of services, including outpatient treatment services and drug 
consumption rooms. Finally, a number of drug services reported that their medical personnel 
had been reallocated to COVID-19 emergency departments. For example, the drug 
consumption room in Oslo was closed because 12 nurses had been reallocated to COVID-19 
medical care in the general healthcare system (see Table 1). 
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■ Difficulties for marginalised clients in accessing essential hygiene-related services. 
Good hygiene is required to reduce the risk of infection, and for this purpose showers, soap 
and clean running water need to be readily available. Respondents indicated that these 
essentials were not always in place for their clients. In addition, some difficulties in accessing 
food and purchasing medications were reported, largely as a consequence of the economic 
difficulties resulting from a reduction in income-generating activities (including begging). 
Overall, experts feared that levels of marginalisation are likely to increase as a consequence 
of COVID-19, while some already marginalised groups who use drugs were likely to 
experience further social erosion. 
■ Challenges linked to the use of remote technology (phone and video). Various remote 
technologies have been strongly promoted as a safer alternative to face-to-face contact 
during the pandemic, and these new opportunities have also been taken up by drug service 
providers. While the benefits of such approaches were evident in relation to maintaining 
contact with clients and providing counselling services, a range of problems also emerged 
during the lockdown period. These included difficulties in convincing both clients and some 
staff to adopt remote technologies. There were concerns expressed around the loss of human 
contact during individual therapy, counselling and group therapy, as traditionally used in a 
number of services. It was also suggested that the use of remote technology could increase 
inequality by excluding those clients and service providers who do not have access to 
computers or mobile phones. More marginalised clients and those with comorbidities were 
considered to be particularly disadvantaged in this respect. There were also some concerns 
among service providers about client-counsellor confidentiality, especially with regard to the 
use of video-based technology. 
■ Difficulties in enrolling new clients. Challenges in enrolling new clients were reported by 
services in a number of countries, and these were highlighted particularly in relation to new 
clients entering residential services, pharmacological detoxification and OST. 
Many residential treatment facilities, such as therapeutic communities, were reported to be 
following a similar approach to other non-drug-related residential care facilities, such as 
retirement homes. This included closing access to the programmes for new clients and a 
reduction in group activities within facilities. In most cases, external visits were suspended, 
and exits for clients finishing their therapeutic journey were delayed. There were, however, no 
reports of residential facilities being hotspots for COVID-19 outbreaks, as nursing homes 
have been in some countries. A particular therapeutic challenge for residential drug services 
has been the need to reduce or stop interventions requiring social proximity or group therapy, 
which often constitute an important part of the therapeutic process in these facilities. 
In addition, pharmacological detoxification requiring hospitalisation was reported to have been 
discontinued in most countries. This is in line with a reduction seen elsewhere in non-
essential hospitalisation affecting a wide range of chronic medical conditions during the 
confinement period. There were also reports from some countries of cases where drug 
addiction wards in psychiatric hospitals, which are typically responsible for carrying out 
pharmacological detoxification, had been requisitioned to support anticipated increases in 
demand for COVID-19-related hospitalisation. 
Finally, initiation of OST for new clients was reported to have been particularly challenging at 
the start of the pandemic, as diagnosis and induction of the treatment generally requires 
several face-to-face meetings between the client and the prescribing doctor. 
■ Managing the demand for substitution treatment. A common priority observed across a 
large number of European countries was the need to ensure that clients already in OST 
continued to have access to this treatment, and that new clients demanding this treatment 
could obtain it (e.g. through low threshold OST programmes). Implementing new policies 
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focusing on ensuring continuity of care involved a significant mobilisation of key actors in the 
field as well as the implementation of innovative approaches at service, community and policy 
levels (discussed later in this briefing). However, for European countries with low OST 
coverage levels and low treatment coverage levels in general prior to COVID-19, it appears to 
have been particularly challenging to implement such policies. Furthermore, some countries 
(Belgium, Czechia and Hungary) reported shortages of OST medications, which, however, 
had already been observed in some cases prior to COVID-19. 
■ Potential for unintended consequences of rapidly implemented adaptations. European 
health services including drug services were largely unprepared for such an unprecedented 
public health crisis as COVID-19, and contingency plans were rarely in place. Service 
adaptations have necessarily been rapidly implemented and it is likely that the full 
ramifications of the measures adopted will emerge only with time. Some concerns were 
raised by study participants, for example, about the potential for increased numbers of fatal 
overdoses due to large take-home doses of OST prescribed by some services, in order to 
reduce visits to pharmacies or clinics. In addition, the focus on securing care for people with 
opioid problems in most countries, and problem stimulant use in a few, may have resulted in 
those with problems with other drugs, cannabis and cocaine users for example, receiving less 
attention during this period. 
 
 
Case study 1: COVID-19 and drug services in Italy – providing services in the eye of the storm 
 
Italy was the first European country to be severely affected by the COVID-19 pandemic. The first case was 
detected on 31 January and the first deaths were recorded on 22 February 2020. As of 4 May 2020, Italy has 
reported 210 717 cases and 28 884 deaths (ECDC, 2020). Within the country, the northern regions were early on 
the epicentre of the epidemic, and quarantine zones, so called ‘red areas’ were put in place to contain its spread.  
For the purpose of this study, a virtual facilitated group with 11 Italian drug professionals explored the challenges 
faced by Italian drug services during the height of the first weeks of the epidemic.  
As a first response, most drug services in Italy were forced to reduce and re-organise their activities. This was in 
part in response to the impact of lockdown measures, with staff shortages resulting from both the transfer of 
personnel to COVID-19 dedicated hospital units as well as staff being infected with the coronavirus. There was 
also a reported reduction in help seeking behaviour, in particular for cocaine, alcohol and cannabis-related 
problems. 
Experts explained how certain drug services were discontinued (e.g. new admissions to residential treatment), 
adapted (e.g. fewer requirements stipulated for take home doses of OST) and in some instances expanded due 
to an increased demand (e.g. outreach units providing services to homeless, sex workers and other marginalised 
groups). COVID-19 infections among clients of the drug professionals participating in the focus group were 
reportedly limited, and with only mild health consequences. Several cases were also reported among their staff. 
Subsequently more stringent prevention measures were implemented by services, including fever scanning 
before allowing access to services, hand-washing and mandatory use of masks.  
Therapeutic communities (TC) play an important role in the Italian drug treatment landscape and Italy has the 
highest number of TCs in Europe (EMCDDA, 2014). In these services, experts highlighted particular challenges 
linked to the management of quarantine restrictions including difficulties providing individual space for self-
isolation, as well shortages of protective material and coronavirus tests. COVID-19 prevention measures also 
interfered with a number of interventions that underpin the therapeutic approach used in this setting.  
Management of the epidemic in prisons was also a challenge early on in the Italian COVID-19 outbreak. Specific 
measures for the management and control of the spread of infections were quickly adopted and, as in other 
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European countries, regulations allowing the early release of detainees were also implemented in Italian prisons. 
However, the prohibition of external visits at the start of the epidemic led to protests. In Modena and Milan 
prisons, people broke into prison pharmacies and ingested large quantities of opioids used to treat drug 
addictions. Nine people died in one day in the Modena’s prison, although toxicological confirmation is on-going 
(ANSA, 2020). 
As observed in other countries, the challenges and adaptations by drug services to this public health crisis was 
reported to have raised some questions that may impact on the future of the Italian drug treatment system. Drug 
professionals expressed the need in the future to consider changing current approaches to the doctor-patient 
relationship and to review traditional models of service provision. They reported that the majority of clients have 
displayed a high level of responsibility in respecting public health measures and adhering to drug treatment, 
including pharmacological treatment, throughout this on-going crisis. 
 
 
How has COVID-19 affected help-seeking and treatment demand? 
A snapshot of the evolution of demand for specialised treatment between January 2020 and March 
2020 provides a first insight into the impact of COVID-19 on drug services and help-seeking. Although 
clearly not representative of, or generalisable to the whole of the EU, available treatment demand 
data from four countries (Bulgaria, Ireland, Lithuania and Portugal) reveal an overall reduction of more 
than 50 % in clients entering drug treatment between January and March 2020 (Figure 6). This 
reduction was particularly marked for opioid users, but, although the numbers are smaller, similar 
reduction rates can be observed for users of other substances (Figure 7). 
FIGURE 6 
Preliminary data on the number of all clients and new clients entering treatment between 
January and March 2020 in four EU countries 
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FIGURE 7 
Preliminary data on all clients entering treatment by main drug between January and March 
2020 in four EU countries 
 
 
The observed decreases in both new and all clients entering drug treatment can be attributed to 
several factors highlighted above. Confinement measures have made it difficult for clients to reach 
treatment centres, and particular problems may exist for people travelling from rural areas, where 
there may be lack of public transport. Furthermore, many treatment centres have been obliged to 
reduce their service provision in order to apply the required COVID-19 prevention and distancing 
measures (reduced opening hours, fewer contacts, etc.) and have been affected by staff shortages. 
There has also been a reported reduction in the range of interventions delivered, and in particular a 
decline in interventions involving prolonged physical contact, such as psychosocial treatment. It was 
also reported that some of the reduction observed among cannabis clients entering treatment was 
likely to be explained by a drop in referrals coming from the criminal justice system in some countries 
during the COVID-19 confinement period. 
This decline in service provision may have been partially compensated for through changes to 
existing modus operandi, as described in the next section. It should, however, be noted that a number 
of countries provided access to OST to new clients through novel low threshold OST programmes 
(see case study 2) and this would not be reflected in the specialised treatment demand data 
presented here. At the beginning of the pandemic there were also difficulties in enrolling new clients 
into OST within specialised treatment centres, which reportedly improved in some countries by mid-
March and April. It will be interesting to see whether future analyses with data for April and May will 
show a rebound in treatment demand. 
In spite of this overall decline reported in help seeking and service availability, some increases in 
opioid users seeking to access OST in the initial phases of the COVID-19 crisis were reported in a 
number of countries, including Czechia, France, Italy and Luxembourg. This was in part linked to a 
possible reduction in heroin availability on the illicit market, but was also associated with the closure 
of some services, which in turn increased pressure on those remaining open.  
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Unlike experts from drug treatment services, those from European harm reduction services 
presented, in general, no changes or even increases in the demand for help-seeking among their 
client groups. Some of the reasons reported included an increase in requests for social support 
(accommodation, food, hygiene, income) and a need to access low-threshold OST (assumed to be 
due to a shortage of heroin on the market in some countries). High levels of client anxiety, which 
some experts posited to be associated with an observed increase in benzodiazepine and alcohol use 
among clients, were also identified as a factor contributing to an increased need for support from 
harm reduction services. 
Some people seeking help were reported to be new to services, and professionals in some countries 
reported an increase in treatment and harm reduction demand from sex workers using drugs and from 
people recently released from prison as part of COVID-19 measures taken by several countries. 
Importantly, large variability in terms of service offer and demand for support were reported between 
countries and also within countries. The situation is also rapidly evolving; in particular, drug 
professionals indicated an increase in specialised treatment demand during the final weeks of April. In 
addition, it is reported that some users, including cannabis and cocaine users, may be becoming 
increasingly aware of their problem substance use as the confinement period is extended. 
 
 
Mini European Web Survey on Drugs — impact of COVID-19 on intention to seek help among people who 
use drugs  
 
The EMCDDA mini European Web Survey on Drugs: Covid-19 aims to collect perspectives from people who use 
drugs on the impact of Covid-19-related restrictions. During the first wave, around 3 700 respondents completed 
the online questionnaire in one of the 21 languages made available between 8 and 27 April 2020. Respondents 
from Estonia, Ireland Spain, Italy, Latvia, Lithuania and Luxembourg) accounted for 80 % of the sample. While 
web surveys are not representative of the general population, when carefully conducted, they can help to paint a 
comprehensive, realistic and timely picture of drug use in Europe and, in the context of this study, the survey 
contributes to the overall analysis of the situation and of the changes associated with the COVID-19 pandemic 
and its consequences. 
In the 30 days prior to responding to the survey, more than half of the sample reported having used some form of 
cannabis product; 10 % reported use of ecstasy/MDMA, cocaine, amphetamines or non-prescribed opioids other 
than heroin. More than 6 % had used heroin during the same period. 
How have COVID-19 confinement measures affected help-seeking behaviours?  
 
The intention to seek professional support to reduce or abstain from use, for example through counselling or drug 
treatment, remained unchanged for most respondents. However, for about 15 % of the sample, the introduction 
of COVID-19 containment measures resulted in either reduced (9 %), or elevated (7 %) intention to seek support. 
Of the countries with most survey respondents, the largest proportion of those with an increased intention to seek 
help came from Ireland (15 %), while Lithuanian respondents showed the greatest reduction (12 %). In parallel, 
6 % of the overall sample reported higher use of remote professional help, including phone-, video- or web-based 
drug services, with most of these respondents living in Spain (19 %) and Ireland (14 %). These numbers may 
reflect factors including changes in respondents’ personal situations and the increased availability of remote 
technology. 
Among the 261 respondents who reported injecting a drug in the previous 12 months, 20 % stated that clean 
injection material had become less accessible as a result of COVID-19 restrictions. Most of the usual sources of 
clean syringes were used less during the weeks after restrictions were imposed (Figure 8). The reduction in use 
is most pronounced for pharmacies, drug consumption rooms and drug dealers. 
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FIGURE 8 
Access to syringes before and after COVID-19 among people who inject drugs — European 
Web Survey on Drugs: COVID-19 (n = 261) 
 
 
European drug services and access to COVID-19-related guidelines and 
recommendations 
In Europe’s health systems, clinical and public health guidelines are used to ensure that evidence-
based interventions are provided to all patients in need. Relatively early in the development of the 
COVID-19 pandemic, several international organisations, including the World Health Organization 
(WHO) and the European Centre for Disease Prevention and Control (ECDC) published public health 
recommendations, which were available for adaptation at the national level. 
Twenty-three European countries reported on the availability of specific guidelines for in drug services 
on responding to the COVID-19 emergency. Of these, eleven countries had rapidly developed specific 
guidance addressing drug services or drug-related problems. Four countries had translated guidelines 
or briefings published by international organisations such as WHO and ECDC (including an update 
published by the EMCDDA). Five countries reported having adapted national guidelines produced for 
health services to the needs of drug services. 
Among the countries reporting some availability of targeted guidelines for drug services or drug-
related problems on responding to COVID-19, a proportion reported the publication of national-level 
guidelines, while in others individual services including non-governmental organisations (NGOs) had 
self-organised and issued their own guidelines. Some national guidelines prioritise populations at 
particular risk. In Czechia, for example, guidelines issued in April 2020 included a focus on off-label 
use of psychostimulants for methamphetamine dependence. During the same period, the Netherlands 
issued guidelines on COVID-19, homelessness and drug use. Luxembourg, in its general health 
guidelines, mentions homeless people and drug users as groups at higher risk of infection. Germany 
has issued guidelines to support an increase in take-home OST, with the aim of reducing crowding in 
drug services. Denmark has released guidelines on the treatment of acute opioid withdrawal, in 
preparation for the possibility that the closure of national borders will reduce the availability of illicit 
heroin. Ireland has also addressed opioid withdrawal and overdoses through the preparation of a 
contingency plan including guidance on the continuation of OST for people in isolation. All the 
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guidelines are available in dedicated national or service web pages making clear reference to the 
COVID-19 emergency. 
What have been the main adaptations and innovations implemented by 
European drug services? 
Preliminary findings from this study reveal a wide range of adaptations made by drug services and 
innovations introduced in terms of service delivery, with many similar characteristics reported across 
European countries. In some countries, both NGOs and civil society organisations are reported to be 
playing a particularly important role. The provision of frontline harm reduction interventions in Europe 
pre COVID-19 was commonly the responsibility of NGOs and, with the emergence of the virus, these 
actors have found themselves at the forefront of the response to COVID-19 for people with more 
severe forms of problem drug use and other health and social comorbidities. It is often reported that, 
in order to be effective, a rapid response to the needs of the drug-using population needs to be based 
on efficient collaboration between NGOs, governmental institutions, and public and private health and 
social service providers; in some cases, this new form of collaboration has been an innovation in itself 
(see Case Study 1). 
However, the extent of the innovations implemented in countries appears to be dependent on the 
national context, including current policies, levels of service provision and available financial 
resources. Examples of new interventions initiated in response to the COVID-19 pandemic include 
first-time distribution of nasal spray naloxone in Portugal, implementation of a mobile drug 
consumption room in Portugal and a temporary drug consumption facility in a shelter in Spain, home 
delivery of OST medications in Ireland, remote prescribing of OST medications in various countries 
and low-threshold OST provision in Luxembourg. 
In general, the main adaptations observed across European drug services involved the 
implementation of preventive measures to reduce the risk of infection, such as social distancing rules, 
use of PPE for staff and structural changes to physical centres to permit visits while maintaining social 
distancing. The adaptations and innovations described below represent some of the main changes 
that have emerged during the confinement period. 
Telemedicine 
As face-to-face counselling and visits to clinics were generally stopped or significantly reduced from 
the start of containment measures, telemedicine by phone or video has been widely embraced as an 
alternative across European drug services (see Figure 9 for the example of a Latvian treatment 
centre). This option was especially beneficial for people with less severe forms of drug use; treatment 
that involves primarily psychological counselling (e.g. for cannabis or cocaine users); first service 
contacts; and long-term stable OST clients. Phone helplines and online professional harm reduction 
forums also provided alternatives for recreational users seeking support during this period.  
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FIGURE 9  
Numbers of face-to-face and phone consultations at the Riga Addiction Medicine Centre, 
Latvia, in March and April 2020 
 
 
Innovations and adaptations in opioid and methamphetamine substitution 
treatment 
It is estimated that nearly 700 000 people currently receive OST in Europe (EMCDDA, 2019). Since 
COVID-19, service providers in the field have had to act rapidly and change the way that OST is 
provided, both to ensure access to medications for those already in treatment and to respond to new 
treatment demands. Several important adaptations have been observed across Europe: 
■ In order to reduce the number of visits to prescribing doctors and clinics, some countries have 
implemented a relaxation of the regulations or legal framework on take-home OST for stable 
OST clients. The changes reported have included prescriptions of OST medications being 
extended for longer periods, prescription of larger quantities, changes in dosages and 
products, and reduction in or no urine testing or supervised intake. Changes in prescribing 
modalities were also reported, with a preference expressed in some cases for electronic 
prescriptions being sent directly to pharmacies. For example, to ensure continued access to 
OST in Ireland during COVID-19, medications are delivered to the client’s home, and a 
photograph is taken using a mobile phone to verify the identity of the recipient and to avoid 
the need for signatures. 
■ In order to ensure access to OST for the most vulnerable clients, outreach through mobile 
OST programmes has been deployed in a number of countries, such as Czechia, Spain, 
Portugal and Slovenia. Provision of rapid access to OST for new clients has been made 
possible through the establishment of new low-threshold programmes, for example in 
Luxembourg (see Case Study 2), and in some cases through modifications to the standard 
OST induction procedures. 
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■ A novel maintenance treatment for methamphetamine has been approved in Czechia, 
involving the prescription of methylphenidate to reduce methamphetamine-related cravings 
(SNN ČLS JEP, 2020). Formal approval was fast-tracked to ensure that methamphetamine-
dependent users seeking treatment could manage abstinence at a time when their access to 
psychosocial and inpatient treatment was disrupted. 
 
 
Case study 2: A new low-threshold OST programme in Luxembourg 
 
In a rapid response to the recent COVID-19 crisis, Abrigado, a Luxembourgish NGO, has developed an 
innovative opioid substitution programme that is the first low-threshold programme in Luxembourg. The service 
includes visits from a doctor three times a week to prescribe medical treatment, and there is childcare provided, 
with a nursery open seven days a week. Abrigado works in close collaboration with a local pharmacy, which 
provides prescriptions of Mephenon, Lysox and Valium. Only adult clients who are not currently enrolled in a 
programme are given access to OST. Some clients visit daily to take their medication; others can take away up to 
three days’ worth of medication at a time. Every client is registered in the service system and each client’s 
treatment journey is documented and adapted as necessary. 
There were a number of drivers behind the rapid implementation of this first low-threshold OST programme, in 
particular an emerging shortage of drugs on the illicit market associated with tighter controls on and the closure of 
national borders. This context provided an incentive for the national authorities and Abrigado’s management to 
cooperate on implementing a substitution intervention offering a medical alternative to illicit substances. All 
parties met several times in March and April and developed a consensus on the beneficial aspects of such a 
service offer. 
 
Source: Lionel Fauchet, Abrigado. 
 
 
Innovation and adaptation in harm reduction services 
Many European harm reduction services have been heavily curtailed as a result of COVID-19 and 
national confinement measures. The majority of European drug-checking services have stopped their 
face-to-face activities but have simultaneously increased their online presence, providing harm 
reduction services for recreational users in home settings. Low-threshold centres and drop-in centres 
have also experienced severe disruption as a result of social and physical distancing measures 
preventing the gathering of clients inside or outside their locations. In order to ensure access to 
essential drug services and harm reduction services, many providers have switched to the promotion 
of remote services or have made adaptations that reduce the need for physical contact. For example, 
some needle and syringe exchange programmes have encouraged users to take away larger 
quantities of injecting material and harm reduction material. Some services in France have used the 
postal system to deliver harm reduction material to users at home. In Split, Croatia, and also 
elsewhere, self-service harm reduction spots have been established to facilitate access to vital 
equipment while reducing physical contact. 
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Self-service spot providing harm reduction 
material, managed by clients themselves, in a low-
threshold service in Split, Croatia, during the 
COVID-19 pandemic 
Source: Nevenka Mardešić, HELP Association. 
Drug worker with PPE in a new mobile drug 
consumption room in Lisbon, Portugal 
Source: Programa de Consumo Vigiado, Grupo de 
Ativistas em Tratamentos and Médicos do Mundo 
 
Most European drug consumption rooms appear to have remained operational throughout the 
lockdown (Table 1), although with important changes to their modus operandi (staff rotation, fewer 
clients at a time, etc.). Portugal and Spain have also seen the introduction of mobile drug 
consumption rooms during this period. 
In many countries, shelters have played a key role in accommodating homeless people during the 
confinement period. Adaptations to shelter rules were often reported as necessary to facilitate access 
for a variety of people, including families with children and people with pets, and measures included 
reducing restrictions on drug and alcohol intoxication. Temporary shelters have also been established 
in some countries by requisitioning hotels, setting up large tents or adapting residential treatment 
facilities. Many services, in particular those working with more marginalised users, have reported 
increased alcohol harm reduction activities as an important adaptation to their services. 
 
TABLE 1 
Preliminary overview of closures and adaptations among drug consumption rooms (DCRs) in 
some EU countries 
Country City Source Status Adaptations to COVID-19 
Norway  
Oslo – Closed None 
Bergen – Closed None 
Germany  
Deutsche 
Aidshilfe 
Most DCRs across Germany 
are open but two are closed 
(Bochum and Troisdorf) 
No information 
Ragazza Women-only DCR open Night shelter closed 
Portugal Lisbon Medicos do Mundo 
DCR is open (extended 
opening hours) Additional mobile DCR implemented 
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Country City Source Status Adaptations to COVID-19 
Spain 
Bilbao Gizakia DCR is open (extended opening hours) 
 
Increased personnel; reduction in 
consumption spaces; every client is 
screened for COVID-19 before entering; a 
special protocol is in place in case of 
suspicion of infection, as well as a 
designated area for people suspected to be 
infected; use of masks and gloves is 
mandatory for all staff members; extra 
hygiene measures are in place; a new OST 
programme has been implemented 
Barcelona Redan — La Mina 
DCR is open (reduced 
opening hours) 
 
The staff have been divided into two teams, 
alternating working days; use of protective 
equipment is mandatory for all staff; 
reduced number of injection spaces; 
additional hygiene rules have been 
implemented; every client is screened for 
COVID-19 before entering; a special 
protocol is in place in case of suspicion of 
infection (isolate and refer to emergency 
room). A new temporary drug consumption 
facility was set up inside a shelter. 
France Strasbourg Ithaque DCR open (normal working hours) 
 
Welcome space is closed; only two clients 
are permitted in the consumption space at 
any time; use of masks is mandatory for 
staff, and staff meetings are held by 
videoconference; shared areas are 
disinfected hourly; fever screening and 
mandatory handwashing are in place; a 
special protocol is in place in case of 
suspicion of infection; there is no limit on 
the volume of single-use drug-use material 
per person  
Netherlands Amsterdam AMOC, De Regenboog 
DCR open (normal working 
hours) 
Additional hygiene measures implemented, 
limited access to the DCR (number of 
people, time spent inside) 
Denmark Copenhagen – DCR open (normal working hours) 
Smoking areas closed, reduced access, 
mobile DCR unit closed 
Luxembourg Luxembourg Abrigado Open 
 
Alternating shifts for five fixed teams of 
seven workers each (and three teams of 
two workers for the night shelter) to reduce 
contacts within the whole team; limited 
access to allow for minimum safe 
distances; use of masks mandatory for staff 
and clients; fever screening for all clients 
entering the night shelter; new OST 
programme implemented  
Source: Survey of DCRs by the Correlation European Harm Reduction Network, April 2020. 
 
 
 
 
 
EMCDDA Trendspotter briefing I Impact of COVID-19 on drug services and help-seeking in Europe 
 
 
18 
 
 
Case study 3: A harm reduction response to COVID-19 among people who use drugs and who are 
homeless in Dublin, Ireland 
In early March 2020, the need to adapt quickly to support the public health response to COVID-19 was identified 
as a priority for frontline services working with people who use drugs and who are homeless in Dublin. The 
Health Service Executive, Dublin City Council and a number of NGOs acted rapidly, and in partnership, to 
establish seven residential units. These were opened in a matter of weeks, for the purpose of isolating 
symptomatic people who were homeless, and to ‘cocoon’ others who were non-symptomatic but who were 
clinically assessed as being vulnerable because they had underlying health conditions. NGO workers were 
redeployed to run these units and a clinical lead was appointed with responsibility for COVID-19 and 
homelessness in Dublin. 
As a result of the initiative, the waiting time for OST (specifically methadone) was reduced from 12 weeks to 
2-3 days for people who were homeless and opioid-dependent. Benzodiazepine stabilisation prescriptions were 
provided for people in isolation/cocooning. Importantly, prescriptions were delivered by two NGOs to people who 
were homeless and isolating in accommodation across Dublin. 
The state’s response of providing accommodation and increasing the accessibility of prescription drugs 
(particularly, but not exclusively, methadone and benzodiazepines) has helped to stabilise people and encourage 
them to remain in isolation, which in turn has contributed to reducing the spread of COVID-19. 
As of 24 April 2020, in Dublin City, among this cohort: 
▪ A total of 33 people had been diagnosed with COVID-19 since the beginning of the crisis 
▪ Three clusters (i.e. two or more cases) of COVID-19 had been identified within homeless 
accommodation, all of these consisting of two cases only 
▪ There had been no known COVID-19 related deaths. 
 
The number of COVID-19 cases among this cohort was lower than had been anticipated; for example, in the 
week of 24 April, nearly 200 COVID-19 cases had been expected, but only four cases were reported. Similarly, 
more clusters of cases within homeless accommodation and some associated deaths had been anticipated. 
For people who use drugs and are homeless, harm reduction has been, and will continue to be, an important part 
of the public health response to COVID-19 in Dublin; it is considered crucial both to help stop the spread of the 
virus and to reduce drug-related harm. 
Sources: Tony Duffin, Ana Liffey Drug Project, and Dr Austin O’Carroll. 
 
 
 
What will be ‘the new normal’ for drug services after the lockdown? 
It is anticipated that during the coming months most European governments will lift the state of 
emergency and gradually ease the confinement measures that their citizens are under. As 
populations learn to live with the coronavirus, it is clear that many preventive and distancing 
measures will need to remain in place to minimise the risk of infection. 
Like other health disciplines (e.g. dentistry, dermatology, etc.), drug services will be expected to 
maintain a broad range of structural and individual health protection measures. It can be expected 
that some of the staffing shortages observed during the confinement period will ease and that it may 
be possible to improve physical access to services, as well as protection for clients, through the 
implementation of a range of service adaptations (e.g. longer opening hours, appointments only, 
mandatory use of masks for all clients, regular disinfection of the premises, no waiting rooms). It has 
already been reported that the European Federation of Therapeutic Communities is drawing up a new 
protocol for welcoming new clients, to be applied from May 2020. 
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It is anticipated that drug services may need to address the needs of clients who were less of a focus 
during the early stages of the COVID-19 crisis, including cannabis and cocaine users. It can also be 
expected that most services will produce contingency plans to maintain operations in case of a 
second wave of COVID-19 infections in their country. 
When asked their opinions on what the post-COVID-19 ‘new normal’ might look like for drug services 
in Europe, many of the experts surveyed expressed cautiously positive views. In many countries the 
crisis was presented as opening a ‘window of opportunity’ which allowed for the initiation of new 
service models and developments. In particular, a number of the rapidly introduced service changes 
were perceived as positive, and respondents considered that it would be advantageous to maintain 
these after the first wave of the crisis has passed. The most commonly cited examples centred on 
continued and future use of telemedicine. Both staff and clients have in a very short time frame 
become accustomed to the use of phone and video technology to provide and receive drug services 
remotely. Nevertheless, it was emphasised that telemedicine needs to be considered as an efficient 
adjunct to, rather than a replacement for, face-to-face therapeutic services for a range of clients in the 
future. 
Several drug treatment experts also mentioned that certain adaptations made to traditional OST 
provision during this period may potentially be more commonly accepted and integrated into new 
national OST approaches post COVID-19. They noted in particular the observed benefits of the 
relaxing of regulations that allowed a greater number of opioid users to access this treatment. Other 
developments reported as positive included reductions in urine testing, daily visits to clinics and 
supervised consumption of medication. A number of experts reflected that it might be difficult to 
medically justify a reversal of these adaptations, as many clinicians observed relatively good 
management of this new treatment approach by their clients. 
Efficient coordination and collaboration between public, private and non-governmental actors during 
this time of crisis was welcomed by contributors and was considered to be particularly beneficial for 
service users. However, the negative forecasts for national economies in the coming months were 
seen as highlighting a particular risk for drug services, with the potential for funding cuts in health 
budgets and a likelihood of increased marginalisation for certain social groups. Nevertheless, many 
respondents remained hopeful that the wide range of changes and gains made during the past 2 
months in terms of innovation and collaboration in the drugs field would become the new normal for 
the foreseeable future in Europe. 
 
Drug-related harms during COVID-19 — EMCDDA trendspotter briefing June 2020 
 
The focus of the next EMCDDA trendspotter briefing will be on the impact of COVID-19 on patterns of drug use 
and harms. 
For people who use drugs, the COVID-19 pandemic may cause a wide range of harms, associated both with pre-
existing health problems that can increase the risk of becoming seriously ill if infected and with factors linked to 
particular drug use behaviours. 
People with chronic opioid and stimulant use problems are more likely to have compromised immune systems, 
chronic respiratory disease — for example linked to smoking tobacco and other drugs — and cardiovascular 
disease (Palmer, 2012; Thylstrup, 2015). People who use drugs who have chronic health problems are both 
particularly susceptible to COVID-19 infection and at greater risk of severe consequences if infected. These 
important issues and more will be explored in depth using the trendspotter methodology, with results made 
available by the EMCDDA in June 2020. 
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Resources on COVID-19 
EMCDDA 
▪ Topics page on COVID-19 and drugs: http://www.emcdda.europa.eu/topics/covid-19  
 
Europe 
▪ ECDC: https://www.ecdc.europa.eu/en/novel-coronavirus-china  
▪ European Commission action and response team: https://ec.europa.eu/info/live-work-travel-
eu/health/coronavirus-response_en 
▪ European Science Media Hub (European Parliament): https://sciencemediahub.eu/ 
▪ WHO Europe: http://www.euro.who.int/en/home 
 
World 
▪ CDC: https://www.cdc.gov/coronavirus/2019-nCoV/index.html and 
https://www.cdc.gov/coronavirus/2019-ncov/community/homeless-shelters/plan-prepare-respond.html 
▪ WHO: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
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